



The Role of Vaccines in Antimicrobial Stewardship Program to Reduce Resistance

Guest Editor:

Prof. Dr. Matteo Bassetti

1. Department of Health Sciences, University of Genoa, 16126 Genoa, Italy
2. Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy

Deadline for manuscript submissions:
closed (31 January 2021)

Message from the Guest Editor

Dear Colleagues,

antimicrobial resistance (AMR) represents an emerging threat to global health, typically associated with high morbidity and mortality rate. According to a recent English report, if AMR is not controlled, 10 million people will die of drug-resistant bacterial infections annually in 2050 worldwide, with a cumulative economic loss reaching \$100 trillion.

Despite vaccines are in a phase of major improvements and technological advances on many fronts, few attention has been paid to vaccines as a new element of antimicrobial stewardship programmes, yet the positive effect in reducing AMR has been well established. Therefore, the objective of this special issue is to look at how vaccines may be used in the fight against AMR, both directly, by reducing the incidence of bacterial infections, and indirectly, by the multiple ways in which they can reduce the use of antibiotics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com